Iverlink — Ivermectin 12 mg

Iverlink 12 is provided as tablets intended for oral administration. The chemical composition includes:

• Active Substance (per 1 tablet): Ivermectin — 12 mg.
• Inactive Excipients: Microcrystalline cellulose, anhydrous lactose, magnesium stearate, sodium starch glycolate, color yellow oxide of iron.
• Dosage Form and Packaging: Circular tablets intended for oral administration. Supplied individually as 1 blister strip containing 10 tablets. The original producer's outer cardboard container holds 10 blisters (100 tablets overall).

Pharmacodynamics: Ivermectin is a semisynthetic derivative of avermectin B1a. It binds selectively and with high affinity to glutamate-gated chloride ion channels found in invertebrate nerve and muscle cells. This interaction increases the permeability of the cell membrane to chloride ions, causing hyperpolarization of the nerve or muscle cell. Ultimately, this results in flaccid paralysis of the parasite, leading to its death and subsequent clearance from the host organism.

Pharmacokinetics: Following oral intake, ivermectin is rapidly absorbed through the gastrointestinal tract, arriving at its maximum plasma concentration (Cmax) within approximately 4 hours. The compound is roughly 93% bound to human plasma proteins (predominantly albumin). Hepatic clearance takes place via metabolism mediated primarily by cytochrome P450 isoenzymes (including CYP3A4). The terminal elimination half-life (T1/2) averages 18 hours. Elimination is almost entirely via feces (approx. 99% as metabolites and unchanged drug) and less than 1% via renal pathways.

Iverlink 12 mg tablets are indicated for administration in adult patient cohorts and pediatric patients weighing over 15 kg experiencing the following parasitic conditions:

• 🔹 Strongyloidiasis: An intestinal infection triggered by the roundworm parasite Strongyloides stercoralis.
• 🔹 Onchocerciasis (River Blindness): A severe helminthiasis infection caused by the parasite Onchocerca volvulus.
• 🔹 Lymphatic Filariasis: Used in combination or mass drug administration schedules to lower microfilariae levels (triggered by Wuchereria bancrofti).
• 🔹 Ectoparasitic Infestations: Severe forms of scabies (caused by Sarcoptes scabiei), including crusted (Norwegian) scabies, as well as pediculosis resistant to topical therapies.

The dosing metrics for Iverlink 12 must be established individually by a specialized physician based on the diagnosis and the patient's body weight. Tablets are swallowed with a sufficient volume of water:

• Administration Rules (CRITICAL): The medication must be consumed strictly on an empty stomach — at least 1 hour prior to or 2 hours following any food intake. Co-administration with food is prohibited, as it unpredictably alters the bioavailability and systemic absorption of ivermectin.
• Standard Treatment Schemes: For strongyloidiasis, the recommended dose is 200 mcg per 1 kg of body weight as a single oral dose (for instance, an adult weighing 60 kg requires 12 mg — exactly 1 tablet). For onchocerciasis, the single dose is 150 mcg per 1 kg of body weight. For scabies, a repeat identical dose may be required 7–14 days later to eradicate newly hatched parasites.
• Restrictions: Children weighing less than 15 kg must not be administered this medication due to insufficient safety validation profiles.

The clinical use of Iverlink 12 tablets is contraindicated under the following conditions:

• ⛔ Hypersensitivity: Known allergic reactions or individual intolerance to ivermectin or any baseline inactive excipient included in the formula.
• ⛔ Blood-Brain Barrier Impairments: Conditions associated with compromised BBB permeability (e.g., African trypanosomiasis, meningitis), as this might cause ivermectin to penetrate the central nervous system.
• ⛔ Age and Weight Restrictions: Children under 5 years of age or pediatric patients weighing less than 15 kg.
• ⛔ Pregnancy and Lactation: Periods of gestation or breastfeeding (safety profiles have not been established).
• ⚠️ With Caution: Exercise clinical care when co-administering drugs that depress CNS function, in severe hepatic or renal diseases, or in heavily immunocompromised patients.

Ivermectin participates in significant drug-to-drug interactions that must be evaluated during concurrent medical therapy:

• ❌ GABA-ergic Medications: Co-administration with barbiturates, benzodiazepines (e.g., diazepam, alprazolam), and valproic acid may potentiate central nervous system depression traits.
• ❌ CYP3A4 Inhibitors and Inducers: Powerful inhibitors of this enzyme (such as ketoconazole or erythromycin) can elevate plasma ivermectin levels, whereas inducers (such as rifampicin) lower its therapeutic concentration.
• ❌ Anticoagulants (Warfarin): Ivermectin may mildly enhance the performance of coumarin-type anticoagulants, necessitating prothrombin time monitoring.

Reproductive restrictions and safety parameters for Iverlink 12:

• Pregnancy: The use of ivermectin during pregnancy is contraindicated. Preclinical animal models have demonstrated teratogenic risks at high doses. Administration is restricted only to emergency cases where maternal life-saving needs outweigh fetal hazards.
• Lactation: Ivermectin passes into human breast milk in low concentrations (under 2% of the administered maternal dose). Due to immature barrier systems in newborns, breastfeeding must be completely suspended for the duration of therapy.
• Fertility: The medication demonstrates no direct negative impact on male or female fertility parameters when maintained within recommended therapeutic dosages.

Administering Iverlink 12 is generally well-tolerated; however, adverse events can surface, frequently linked to the rapid degradation of dying parasites:

• 🟢 General and GI Symptoms: Nausea, vomiting, abdominal pain, diarrhea, anorexia, dizziness, somnolence, asthenia, or mild tremors.
• 🟡 Mazzotti Reaction (in Onchocerciasis): A specialized immune response to microfilarial death, manifesting as severe pruritus, skin rash, urticaria, fever, painful lymphadenopathy, tachycardia, and postural hypotension.
• 🟠 Ophthalmological Reactions: Conjunctivitis, ocular edema, abnormal sensations in the eye, or transient reductions in visual acuity (commonly observed during river blindness management).
• ⚠️ Urgent Measures: If a sharp drop in blood pressure, severe allergic urticaria, or loss of motor coordination occurs, contact emergency medical services immediately.

Exceeding recommended ivermectin dosages triggers severe toxic reactions within the central nervous system:

• Symptomatology: Accidental or intentional overdose triggers central nervous system toxicity markers, including severe vertigo, headache, ataxia (coordination loss), paresthesia, dyspnea, nausea, and vomiting. Critical cases can involve seizures, altered consciousness, coma, and severe arterial hypotension.
• Management: There is no specialized antidote. Immediate gastric lavage (if performed shortly after ingestion) and activated charcoal intake are indicated. Intensive supportive and symptomatic protocols are applied (fluid restoration, respiratory and blood pressure maintenance). Avoid using GABA agonists (such as benzodiazepines) when managing seizures induced by ivermectin toxicity.

To preserve the structural stability and potency of Iverlink 12 tablets, maintain the following conditions:

• 🌡️ Temperature Controls: Store in a dry environment shielded from light at a temperature not exceeding 30 °C.
• 👶 Safety Precautions: Keep the original blister strips completely out of the reach and sight of children, adolescents, and domestic pets.
• 📦 Blister Handling: Since this medication is sold individually (as 1 blister strip), extract a tablet from its pocket immediately prior to consumption. Do not store compromised blister strips in humid environments.
• ⏳ Shelf Life: 3 years from the date of manufacture. Do not take the medication past the expiration date printed on the cardboard package and blister backing.